Report highlights growing pains. Revenues low, liabilities high. Financing issues. I think we generally suspected this reality but were hoping for a surprise. As a matter of interest I also noted this: “We plan to finalize our corporate acquisition strategy and to initiate the spin-out process for NGIO in the second quarter of 2020.”
Patience is a key requirement here for GNBT shareholders.
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links